Transpire Bio's ANDA for Generic High-Strength Trelegy® Ellipta® Accepted for Filing by the U.S. FDA
Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled therapeutics for pulmonary and ...
inbrija-1 Inbrija (levodopa inhalation powder; Acorda Therapeutics) is the first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease ...
ProAir Digihaler ProAir® Digihaler® (albuterol sulfate; Teva) Inhalation Powder is now available for patients aged ≥4 years for the treatment or prevention of bronchospasm with reversible obstructive ...
The formulation is being developed in collaboration with United Therapeutics Corporation United Therapeutics made an additional $5 million ...
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...
MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...
Scientific research will highlight advances in dry powder inhaler (DPI) platform products, patient-centric design and ...
March 2, 2006 — The US Food and Drug Administration (FDA) has approved orphan drug status for amphotericin B inhalation powder in the prevention of pulmonary fungal infections in patients at risk for ...
To ensure compliance with the prescribed inhaler regimen and correct inhaler administration, patients should be prescribed an inhaler that they can and will use. This is the theme of the recently ...
FDA's approval of YUTREPIA paves the way for prescribers to add a new treatment option for patients with PAH and PH-ILD YUTREPIA is designed to enhance deep-lung delivery with an easy-to-use device ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results